Cargando…
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma
BACKGROUND: Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis. METHODS: We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enroll...
Autores principales: | Cantor, Evan, Wierzbicki, Kyle, Tarapore, Rohinton S, Ravi, Karthik, Thomas, Chase, Cartaxo, Rodrigo, Nand Yadav, Viveka, Ravindran, Ramya, Bruzek, Amy K, Wadden, Jack, John, Vishal, May Babila, Clarissa, Cummings, Jessica R, Rahman Kawakibi, Abed, Ji, Sunjong, Ramos, Johanna, Paul, Alyssa, Walling, Dustin, Leonard, Marcia, Robertson, Patricia, Franson, Andrea, Mody, Rajen, Garton, Hugh J L, Venneti, Sriram, Odia, Yazmin, Kline, Cassie, Vitanza, Nicholas A, Khatua, Soumen, Mueller, Sabine, Allen, Joshua E, Gardner, Sharon L, Koschmann, Carl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340643/ https://www.ncbi.nlm.nih.gov/pubmed/35137228 http://dx.doi.org/10.1093/neuonc/noac030 |
Ejemplares similares
-
EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201
por: Cantor, Evan, et al.
Publicado: (2021) -
Cell-Free Tumor DNA (cf-tDNA) Liquid Biopsy: Current Methods and Use in Brain Tumor Immunotherapy
por: Wadden, Jack, et al.
Publicado: (2022) -
DIPG-08. ELECTRONIC SEQUENCING PROVIDES OPTIMIZED QUANTIFICATION OF SERIAL, MULTI-GENE MOLECULAR RESPONSE IN THE CSF OF CHILDREN WITH HIGH-GRADE GLIOMA
por: Bruzek, Amy, et al.
Publicado: (2020) -
Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine
por: Schwark, Kallen, et al.
Publicado: (2022) -
DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)